Home » Authors » Brady Huggett

Articles by Brady Huggett

RenaMed Forms Deal With Genzyme For Up To $43M

Sep. 29, 2005

By Brady Huggett

Kereos Raises $19.5M To Both Detect, Treat Disease

Sep. 20, 2005

By Brady Huggett

Kereos Raises $19.5M To Both Detect, Treat Disease

Sep. 20, 2005

By Brady Huggett

Caliper Adding Size Through $22M NovaScreen Purchase

Sep. 9, 2005

By Brady Huggett

Caliper Adding Size Through $22M NovaScreen Purchase

Sep. 9, 2005

By Brady Huggett

Angry Merck Jurors Point To Public's Distaste For Pharma

Sep. 2, 2005

By Brady Huggett

With Discovery Firms Worth Nothing,' Is Biotech Troubled?

Aug. 12, 2005

By Brady Huggett

With Discovery Firms Worth Nothing,' Is Biotech Troubled?

Aug. 12, 2005

By Brady Huggett

Dyax's Phase I, II DX-88 Data Raise Hopes For Pivotal Trial

July 1, 2005

By Brady Huggett

Dyax's Phase I, II DX-88 Data Raise Hopes For Pivotal Trial

July 1, 2005

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...